Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (1013)	7/15/1998 5:14:00 PM
From: Zvi Steinberg	Read Replies (3) \| Respond to of 1491

Yosi, 2Q earnings should be out towards the end of June.results will be very encouraging. good sales Nos from Lotemax and Alrex. Both drugs are slightly ahead of sales projections to date. results of Ph 2 unblinding may be presented at the Largest neurological conference in mid Oct where pharmos will be a presenter. Two smaller brokerage firms are now doing due diligence evaluating Pharmos for coverage. likely to have covereage by sept. The larger firms, Alex brown included, say they need to see a trend of rising revenues from eye drugs sales and known results from Ph 2 unblinding before comitting to coverage. regarding the latest price performance: PARS is not marginable and cannot be shorted. Only Market Makers whose role it is to maintain an orderly market can short a non marginable stock. this is a speculation but there could be some collusion on the part of the Castle Creek partners, our latest private placement, with some MM to make the stock price go down ahead of them converting their shares at 10% discount to the Then current market price. That will be a coup for them if the could convert and buy stock at $2-2.25 ahead of all the expected good news we should have between now and the end of the year. These are thoughts of someone who is very knowledgeable.

To: yosi s who wrote (1013)	7/15/1998 5:43:00 PM
From: Ariella	Respond to of 1491

Dear Yosi, Hope you're enjoying vacation with your family. We broke important support levels in the past few days. I too hope Q2 report will bring some hope back to the thread. Regards, Ariella

To: yosi s who wrote (1013)	7/16/1998 1:50:00 AM
From: Ariella	Read Replies (1) \| Respond to of 1491

To all: Someone who does not post publicly on this thread has sent me a very interesting private message, wondering if this week's TIME note on tamoxifen might be partially responsible for the weakness in the stock price. The note is interesting in two respects. First, it raises a real possibility for the softness in trading. Second, by chasing down the referenced note, I find out how much gets lost in translation when medical journals are "dumbed down" for the general public (us) to read. Here is the TIME news brief: pathfinder.com : <<July 20th edition TIME magazine: BAD NEWS ON BREAST CANCER Tamoxifen, used to treat breast cancer, made headlines in April when a study suggested it could also prevent the disease. But this week, two European studies showed no proof of prevention, casting doubt on earlier hopes. The studies differed in duration (the U.S. study was shorter) and in participants (one European study included low-risk women). >> NewScientist, which I have referenced previously in connection with reports on marijuana-derived drugs, prints the news this way: newscientist.com newswire <<MIXED MESSAGES Does the drug tamoxifen prevent breast cancer in women at high risk of contracting the disease? Now that two European studies have cast doubts on positive results from an earlier American trial, doctors seem further than ever from the answer. Researchers at the Royal Marsden Hospital in London and the European Institute of Oncology in Milan report in The Lancet (vol 352, p 93 and p 98) that tamoxifen performs no better as a preventive medicine than does a placebo. In May, however, the larger American Breast Cancer Prevention Trial was stopped when evidence emerged of a 45 per cent cut in breast cancer incidence among women given tamoxifen. >> Both briefs leave this reader with the feeling that tamoxifen is not a good drug and that something was wrong with the American study if it had to be stopped. Actually, both briefs stem from the July 11 article in the prestigious medical journal LANCET. thelancet.com This is definitely worth a read if you are a serious PARS investor. Its tone and conclusions seem rather opposite to those presented in the more popular press. For instance it asks the question if the two European studies (in Britain and in Italy) were too small to detect the difference seen in the American study (BCPT). It concludes that << the BCPT findings seem robust. They are internally consistent and, perhaps most convincingly, highly consistent with the 47% preventive effect of 5 years of tamoxifen found in the Early Breast Cancer Trialists Collaborative Group (EBCTCG) overview.>> It ends, however, with a warning that more clinical study is needed before tamoxifen is widely prescribed. So, while this news might have had something to do with the price weakness in PARS shares this week, I don't think our tamoxifen analog program should be consider devalued or derailed at all. Most likely nearer term questions about Alrex and Lotemax will determine the direction of the stock price until HU-211 info is released in the fall. --Ariella P.S. By the way, the American study was stopped short because such a definite improvement was found in women who used tamoxifen that the scientists involved did not think it ethical to withhold the drug from the groups assigned to placebo.